GlassScriptPhysician profile
Michael J Mcnamara
NPI 1083601397
$150,148.43
in general payments reported to CMS, 2019-2025
5 companies · $28K in 2025
The $28K reported for 2025 was more than what 82% of Orthopaedic Surgery of The Spine providers received nationally (typical 2025 total: $2,116).
See the full distribution for Orthopaedic Surgery of the Spine
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $76K · 2020: $86.12 · 2021: $7,879 · 2022: $2,778 · 2023: $13K · 2024: $23K · 2025: $28K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Royalty Or License: $60K · Consulting Fee: $2,925 · Food and Beverage: $554.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Royalty Or License | $60,139.00 |
| Consulting Fee | $2,925.00 |
| Food and Beverage | $553.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nexxt Spine LLC | $149,428.89 | 2019-2025 | Connexx Open System, Connexx Pedicle Screw System, Transition |
| Seaspine Orthopedics Corporation | $491.22 | 2021-2022 | |
| Cerapedics INC. | $174.62 | 2019 | |
| Zimmer Biomet Holdings, INC. | $39.07 | 2019 | |
| Pfizer INC. | $14.63 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$91,381.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Mcnamara listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.